Drug firms will have to reveal full cost of new treatments to NICE

Drug companies will be expected to produce evidence of 'the total cost to the NHS' of adopting new treatments under a proposed appraisal process for the National Institute for Clinical Excellence.

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of HSJ.co.uk and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here